One location for all of the downloadable files available from this site, including:
- Animations on acromegaly and carcinoid syndrome
- Patient education booklets on acromegaly and carcinoid syndrome
- Instructional booklets on injecting Sandostatin® LAR Depot (octreotide acetate for
injectable suspension) (for healthcare providers) - Useful forms for filing claims
Animations
View animations about acromegaly, carcinoid syndrome, and how Sandostatin® LAR Depot works. You will need the Flash Player to view the animations.
 |
Acromegaly (832KB) Duration: 1 min See how Sandostatin® LAR Depot works at the site of the tumor to control key pathophysiologic aspects of acromegaly. |
 |
Carcinoid Syndrome (763KB) Duration: 1 min 35 sec See how Sandostatin® LAR Depot works to suppress the overproduction of certain peptides and amines associated with carcinoid syndrome. |
Patient Education Booklets on Acromegaly and Carcinoid Syndrome for Healthcare Providers
Novartis is committed to helping you support patients who are taking Sandostatin® LAR Depot, or those who you are considering starting on the treatment. Healthcare providers may download versions of:
Take Control of Acromegaly (PDF 1,284KB) —a patient's guide to the disease and its treatment
Understand the Symptoms, Gain Control (PDF 1,128KB) —a patient's guide to carcinoid syndrome and its treatment
Instructional Booklets
Download instructional booklets on injecting Sandostatin® LAR Depot:
Successful Injections Help Ensure Successful Treatment (PDF 161KB) —shows how to inject Sandostatin® LAR Depot
Useful Forms
Downloadable forms:
Complete an application form (PDF 194KB) to enroll a patient in the Sandostatin® Starter Program
Easy Access Program Service Request Form (PDF 100KB) to order Sandostatin® LAR Depot
Form CMS-1500 (PDF 361KB) to request reimbursement for Sandostatin® LAR Depot in a private office setting
Important Safety Information
Carcinoid Syndrome:
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported.
The controlled clinical trials that support the marketing clearance for Sandostatin® LAR Depot did not include determination of effect on tumor size or rate of growth. Sandostatin® LAR Depot is not indicated for tumor shrinkage.
Acromegaly
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
